FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
Forte Biosciences (NASDAQ: FBRX) reported Q1 EPS of ($0.36), $0.16 better than the analyst estimate of ($0.52).
Forte has continued to make excellent progress in the fist quarter of 2021. As we have previously highlighted, our randomized clinical trial of FB-401 in atopic dermatitis patients 2 years of age... More

